Grifols (NASDAQ:GRFS) Hits New 52-Week Low at $7.27

Grifols, S.A. (NASDAQ:GRFSGet Rating) shares reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $7.27 and last traded at $7.41, with a volume of 7468 shares trading hands. The stock had previously closed at $7.74.

Analyst Upgrades and Downgrades

GRFS has been the topic of several research analyst reports. Jefferies Financial Group began coverage on Grifols in a research note on Monday, July 25th. They set a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on Grifols from €17.00 ($17.35) to €16.00 ($16.33) and set a “hold” rating on the stock in a report on Tuesday, August 2nd. JPMorgan Chase & Co. dropped their target price on Grifols from €11.50 ($11.73) to €10.30 ($10.51) in a report on Wednesday, September 14th. Finally, Berenberg Bank boosted their target price on Grifols from €20.15 ($20.56) to €20.30 ($20.71) and gave the stock a “buy” rating in a report on Friday, July 15th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Grifols currently has a consensus rating of “Hold” and an average price target of $15.53.

Grifols Stock Down 7.8 %

The company has a 50 day moving average price of $8.76 and a two-hundred day moving average price of $10.66. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.68 and a quick ratio of 0.91. The stock has a market cap of $4.91 billion, a PE ratio of 6.70 and a beta of 0.31.

Institutional Trading of Grifols

A number of hedge funds have recently bought and sold shares of GRFS. Captrust Financial Advisors increased its position in Grifols by 153.5% during the second quarter. Captrust Financial Advisors now owns 2,086 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 1,263 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Grifols by 40.0% during the first quarter. PNC Financial Services Group Inc. now owns 10,530 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 3,010 shares during the last quarter. Alan B. Lancz & Associates Inc. purchased a new stake in Grifols during the second quarter valued at $131,000. Advisor Group Holdings Inc. increased its position in Grifols by 16.3% in the first quarter. Advisor Group Holdings Inc. now owns 11,574 shares of the biotechnology company’s stock worth $135,000 after buying an additional 1,619 shares in the last quarter. Finally, Wetherby Asset Management Inc. purchased a new position in shares of Grifols during the 1st quarter valued at about $140,000. Hedge funds and other institutional investors own 14.62% of the company’s stock.

About Grifols

(Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

Featured Articles

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.